Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) FCF Margin (2023 - 2025)

Immunome (IMNM) has disclosed FCF Margin for 3 consecutive years, with 1247.72% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, FCF Margin fell 29726.0% year-over-year to 1247.72%, compared with a TTM value of 2890.13% through Dec 2025, down 163363.0%, and an annual FY2025 reading of 2890.13%, down 163363.0% over the prior year.
  • FCF Margin was 1247.72% for Q2 2025 at Immunome, up from 1833.46% in the prior quarter.
  • Across five years, FCF Margin topped out at 1013.11% in Q1 2023 and bottomed at 1833.46% in Q1 2025.
  • Average FCF Margin over 3 years is 790.67%, with a median of 1099.09% recorded in 2025.
  • The sharpest move saw FCF Margin crashed -230893bps in 2024, then tumbled -29726bps in 2025.
  • Year by year, FCF Margin stood at 453.45% in 2023, then crashed by -213bps to 1417.79% in 2024, then increased by 12bps to 1247.72% in 2025.
  • Business Quant data shows FCF Margin for IMNM at 1247.72% in Q2 2025, 1833.46% in Q1 2025, and 1417.79% in Q4 2024.